Key facts
- HepaRegenix’s last known valuation is $43.2M (Jan 2020).
- It has raised $45.3M; the latest was Later Stage VC ($23.6M) in Apr 2025.
- Notable investors include High-Tech Gründerfonds, Novo Holdings, Boehringer Ingelheim Venture Fund, Wellington Partners, Ascenion — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for HepaRegenix
- ·The full record, as it builds
Funding rounds
No funding rounds for HepaRegenix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HepaRegenix
Developer of novel therapies designed to treat acute and chronic liver diseases. The company offers small-molecule drug development based on targeting regulatory pathways involved in liver regeneration and cellular repair to create therapies for treating acute and chronic liver diseases, enabling patients with liver conditions and healthcare providers to improve recovery of liver function and support treatment outcomes.
- Sector
- Healthcare
- HQ
- Tubingen, Germany
- Founded
- 2015
- Employees
- 10
- Website
- heparegenix.com/
- Ownership
- Privately Held (backing)
HepaRegenix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HepaRegenix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HepaRegenix in its N-PORT filings yet. We sweep new filings monthly.